Epigenetic Events of Disease Progression in Head and Neck Squamous Cell Carcinoma
Authors:
- Maria J. WorshamMWMaria J. Worsham
- Kang Mei ChenKCKang Mei Chen
- Venkata MeduriVMVenkata Meduri
- Anders O. H. NygrenANAnders O. H. Nygren
- Abdellatif ErramiAEAbdellatif Errami
- Jan P. SchoutenJSJan P. Schouten
- Michael S. BenningerMBMichael S. Benninger
Open Access
- 1 June 2006
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Otolaryngology–Head & Neck Surgery
- Vol. 132 (6) , 668-677
Abstract
Commonly arising in the lips, oral cavity, and larynx, head and neck squamous cell carcinoma (HNSCC) is one of the most prevalent cancers in the world, with over 500 000 cases diagnosed annually. In the United States alone, it accounts for nearly 3.2% of all newly diagnosed cancers. Not only one of the most ubiquitous, HNSCC is also one of most lethal cancers, responsible for 2.1% of all cancer deaths in the United States, and is noted as the sixth most common malignant disease worldwide.1 As such, our focus has been on the identification of an informative set of genetic alterations, including aberrant methylation, that underlie the development and progression in HNSCC. In the present study, we concentrate on gene-silencing events in the contribution of head and neck cancer tumorigenesis. Hypermethylation is a well-described DNA modification that has been implicated in normal mammalian development,2,3 imprinting,4 and X chromosome inactivation.5 However, recent studies have identified hypermethylation as a probable cause in the development of various cancers.6-8 Aberrant methylation by DNA-methyltransferases in the CpG islands of a gene's promoter region can lead to transcriptional repression akin to other abnormalities such as a point mutation or deletion.9 This anomalous hypermethylation has been noted in a variety of tumor-suppressor genes (TSGs), whose inactivation has led many cells down the tumorigenesis continuum.10-12 Numerous TSGs have been implicated as targets for methylation in other cancers,13-15 Promoter hypermethylation of genes in HNSCC have been reported for p16, p14, DAPK, RASSF1A,16-22RARβ2,23,24MGMT, a DNA repair gene that functions to remove mutagenic (O6-guanine) adducts from DNA,25 and E-cadherin, a calcium-dependent cell adhesion molecule that functions in cell-cell adhesion, cell polarity, and morphogenesis.26 However, gene silencing via hypermethylation is still a relatively new idea in the development of HNSCC, and little is known about the contribution of epigenetics to disease progression in HNSCC.Keywords
This publication has 32 references indexed in Scilit:
- Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemiaBlood, 2004
- Tumor-Specific Methylation in Bronchial Lavage for the Early Detection of Non-Small-Cell Lung CancerJournal of Clinical Oncology, 2004
- Detection of Promoter Hypermethylation of Tumor Suppressor Genes in Urine from Kidney Cancer PatientsAnnals of the New York Academy of Sciences, 2004
- Differential targets of CpG island hypermethylation in primary and metastatic head and neck squamous cell carcinoma (HNSCC)Journal of Medical Genetics, 2003
- Relationship Between Transcription and DNA Methylation2000
- Cancer-epigenetics comes of ageNature Genetics, 1999
- Role for DNA methylation in genomic imprintingNature, 1993
- Increased Cytosine DNA-Methyltransferase Activity During Colon Cancer ProgressionJNCI: Journal of the National Cancer Institute, 1993
- Targeted mutation of the DNA methyltransferase gene results in embryonic lethalityCell, 1992
- In vivo footprint and methylation analysis by PCR-aided genomic sequencing: comparison of active and inactive X chromosomal DNA at the CpG island and promoter of human PGK-1.Genes & Development, 1990